These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33009502)

  • 1. Deep phylogeny of cancer drivers and compensatory mutations.
    Rochman ND; Wolf YI; Koonin EV
    Commun Biol; 2020 Oct; 3(1):551. PubMed ID: 33009502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular evolution of cancer associated genes in mammals.
    MacDonald N; Raven N; Diep W; Evans S; Pannipitiya S; Bramwell G; Vanbeek C; Thomas F; Russell T; Dujon AM; Telonis-Scott M; Ujvari B
    Sci Rep; 2024 May; 14(1):11650. PubMed ID: 38773187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Epistasis in Cancer Genomes: A Delicate Affair.
    van de Haar J; Canisius S; Yu MK; Voest EE; Wessels LFA; Ideker T
    Cell; 2019 May; 177(6):1375-1383. PubMed ID: 31150618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
    Chen W; Li Y; Wang Z
    Sci Rep; 2018 May; 8(1):8256. PubMed ID: 29844492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.
    Babenko VN; Basu MK; Kondrashov FA; Rogozin IB; Koonin EV
    BMC Cancer; 2006 Feb; 6():36. PubMed ID: 16469093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.
    Baeissa H; Benstead-Hume G; Richardson CJ; Pearl FMG
    Oncotarget; 2017 Mar; 8(13):21290-21304. PubMed ID: 28423505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.
    Reva B
    BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S8. PubMed ID: 23819556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.
    Van den Eynden J; Fierro AC; Verbeke LP; Marchal K
    BMC Bioinformatics; 2015 Apr; 16():125. PubMed ID: 25903787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.
    Khan MM; Rydén AM; Chowdhury MS; Hasan MA; Kazi JU
    Gene; 2011 Sep; 483(1-2):29-35. PubMed ID: 21640173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed genetic instability: a tumor-permissive mechanism for maintaining the evolvability of higher species through methylation-dependent mutation of DNA repair genes in the male germ line.
    Zhao Y; Epstein RJ
    Mol Biol Evol; 2008 Aug; 25(8):1737-49. PubMed ID: 18535014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
    Ma M; Wang C; Glicksberg BS; Schadt EE; Li SD; Chen R
    Pac Symp Biocomput; 2017; 22():473-484. PubMed ID: 27896999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why Are Some Driver Mutations Rare?
    Nussinov R; Tsai CJ; Jang H
    Trends Pharmacol Sci; 2019 Dec; 40(12):919-929. PubMed ID: 31699406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolution of Human Cancer Gene Duplications across Mammals.
    Tollis M; Schneider-Utaka AK; Maley CC
    Mol Biol Evol; 2020 Oct; 37(10):2875-2886. PubMed ID: 32421773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Towards an inventory of oncogenic mutations in cancer].
    Theillet C
    Bull Cancer; 2010 Nov; 97(11):1223-9. PubMed ID: 21059490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
    Wang X; Zhang Y; Han ZG; He KY
    Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of compensatory mutation in the DNA bacteriophage phiX174.
    Poon A; Chao L
    Genetics; 2005 Jul; 170(3):989-99. PubMed ID: 15911582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors.
    Newberg JY; Black MA; Jenkins NA; Copeland NG; Mann KM; Mann MB
    Nucleic Acids Res; 2018 Sep; 46(16):e94. PubMed ID: 29846651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer genes.
    Vogt PK
    West J Med; 1993 Mar; 158(3):273-8. PubMed ID: 8460509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.